PHAT Phathom Pharmaceuticals Inc

$PHAT this indication looking likely combined with FCF positive next year should inspire a more assertive bid next year. This Voquezna P-Cab ecosystem being built by PHAT will be worth $4-$5 billion given TAM the next 7-8 yrs.

$PHAT this could be the exact data/presentation we’re looking for. Highlighting how ridiculous PPIs are and how much the drug costs over time compared to the far superior compound of Voquezna and the tangible healing effects. NET/NET - $PHAT Treatment SAVES patients and insurers. GIs would be wise to phase off PPIs and use Voquezna as it works better, heals damage, and has a BETTER safety profile. Cost-Effectiveness of Vonoprazan Versus Proton Pump Inhibitors in Adults With Erosive Esophagitis in the United States: A Markov Model of Lifetime Outcomes Poster: P5160 Time: 10:30 AM – 4:00 PM CDT Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine

$PHAT are people waking up to what a stupid valuation we’re at now? Company will do $1 in earnings next year. Just buy and hold!

$PHAT Our short interest has dropped by significant amounts, yet our price has also gone down. I would’ve liked to see price recovery along with short covering, but that is not the case. I’m obviously simplifying the dynamic, but I will admit, not a fan of that.

$PHAT Reached 20k shares at an $8.64 average. This still feels like no mans land and it may go lower, but if there is one thing I’ve learned is that I’ll never time anything perfectly.

$PHAT not often gonna find 300m+ revenue per year 75% growth YoY trading below 600m MC. Some will say concerns around debt and potential compotetion in 2027 will slow growth... not to zero. Debt is high but managable with out refinacing given even slower growtg and inflation helps this company. I dont know how this trades below 1B and isnt a 1.5B BO target on the low side. With everyone looking for a place to put money that will beat inflation and bond rate returns, like being able to buy at this price.

$PHAT So many sad sacks in here. I bought 500 at 6.83 and that’s all it took to break the downtrend. They would not fill 500 more at 6.81. It is complete manipulation with just a handful of shares people

$PHAT this is going to get bought by a company that can negotiate with managed care. Current price was similar to when their patent future was uncertain.

$PHAT but but but Steve is doing such a great job!! We can do 1B, no make that 2B in sales. We just have to cut guidance first , then we can get there. It’s just temporary. Trust me. lol. Absolute used car salesman. He better hit any bid he gets (after he speaks with the sales manager of course )!

$PHAT finally listened to the chat. Again, I really do like the the way Basta communicates. It all seems very clear to me. When directly asked about the disconnect, this was his answer. “It’s awkward as a ceo to talk about what price our stock should be. I do see that there is a valuation disconnect. Stock price is trading at a lower price today than it was a year ago. That doesn’t make any sense to me. I think we are creating value by virtue of growing the top line revenue meaningfully, expenses under control, operating profit, positive cash flow next year. When that gets reflected in our price, that’s up to the investment community.”

$PHAT ok mudhaphukkas!!!!!! I am ready to blow my last and final BIG load on this biznitch! sorry just chiming in my inner Nitin I have huge orders in at just below $8 come and get em...jsut put a mid sizing order here at $8 just in case so I dont get fomo's by the MM mofos!

$PHAT Phathom’s Presentations at ACG 2026: Sunday, October 11, 2026 Vonoprazan Efficacy Across BMI Subgroups in Non-Erosive Reflux Disease Poster: P0624 Time: 3:30 PM – 7:00 PM CDT Presenter: Catiele Antunes, MD, Assistant Professor of Medicine and Director of the Refractory GERD Clinic at Yale School of Medicine

$PHAT machines flipping Pennies, SP doesn’t make sense. If they can pull off a manged care win with a big PBM and show a profit this is off to the races!!!

$PHAT generated a lot of cash today as I prepare to reposition from commercial stage cash drains to on the cusp of profitable 💎 like PHAT. Money going in heavy this week which will be my final blow down here.

$PHAT Once again, a small buy scares the algos into immediately bumping the price, then slowly walking it back down. 49 share purchase at 6.685 made them immediately reprice to 6.74. They are counting on you capitulating like a bunch of long tail cats in a room of rocking chairs

$PHAT All this Doom and gloom talk convinced me to pick up another 1400. Looking forward to seeing the updated short figures and the new 13fs next month.

$PHAT either the quant algos have this in free fall or a lot of people know something that hasnt publicly been disclosed.

$PHAT this the position that everyone on Cafepharma indicated the prior person was committing embezzlement and got fired for?

$PHAT Tuesday, October 13, 2026 Cost-Effectiveness of Vonoprazan Versus Proton Pump Inhibitors in Adults With Erosive Esophagitis in the United States: A Markov Model of Lifetime Outcomes Poster: P5160 Time: 10:30 AM – 4:00 PM CDT Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine Attendees can also visit Phathom’s Medical Affairs and Commercial teams on the exhibit floor at Booth 323.

$PHAT Monday, October 12, 2026 Characteristics of US Patients With Gastroesophageal Reflux Disease (GERD) Taking Vonoprazan or a Prescription Proton Pump Inhibitor (PPI) Poster: P2921 Time: 10:30 AM – 4:15 PM CDT Presenter: Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology and Bozymski-Heizer Distinguished Professor of Medicine at the UNC School of Medicine VOQUEZNA® (vonoprazan) Product Theater: Beyond the Data: From Clinical Cases to Patient Perspectives Location: Booth #117 – ACG Product Theater Time: 3:45 PM CDT Presenters: John E. Pandolfino, MD, MSCI, Chief of Gastroenterology and Hepatology and Hans Popper Professor of Medicine at Northwestern University Feinberg School of Medicine; and a Patient Speaker